<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556357</url>
  </required_header>
  <id_info>
    <org_study_id>Yi Chen-2020-4</org_study_id>
    <nct_id>NCT04556357</nct_id>
  </id_info>
  <brief_title>Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia</brief_title>
  <official_title>Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia Undergoing Cesarean Section: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of norepinephrine for&#xD;
      prophylaxis against postspinal anesthesia hypotension in parturients with preeclampsia&#xD;
      undergoing cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia, which affects 5% to 7% of parturients, is a significant cause of maternal and&#xD;
      neonatal morbidity and mortality. Because of constricted myometrial spiral arteries with&#xD;
      exaggerated vasomotor responsiveness, though blood pressure in parturients with preeclampsia&#xD;
      are apparently higher than healthy parturients, placental hypoperfusion is more common.&#xD;
      Spinal anesthesia is still the preferred mode of anesthesia in parturients with preeclampsia&#xD;
      for cesarean section. In preeclampsia parturients, spinal anesthesia improve intervillous&#xD;
      blood flow (provided that hypotension is avoided) which contribute to increase placental&#xD;
      perfusion. Even so, 17-26% parturients with preeclampsia experienced postspinal anesthesia&#xD;
      hypotension due to the extensive sympathetic block that occurred with spinal anesthesia. As a&#xD;
      potential substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction&#xD;
      for use in parturients undergoing cesarean section. But the efficacy and safety in&#xD;
      parturients with preeclampsia is still unknown. The purpose of this study is to investigate&#xD;
      the efficacy and safety of norepinephrine for prophylaxis against post-spinal anesthesia&#xD;
      hypotension in parturients with preeclampsia undergoing cesarean section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of bradycardia</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Heart rate &lt; 60 beats/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall stability of systolic blood pressure control versus baseline</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Evaluated by performance error (PE)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall stability of heart rate control versus baseline</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Evaluated by performance error (PE)</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of postspinal anesthesia hypotension</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 80% of the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of severe post-spinal anesthesia hypotension</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 60% of the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of nausea and vomiting.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Presence of nausea and vomiting in patients after spinal anesthesia</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of hypertension</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &gt;120% of the baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>pH</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Partial pressure of oxygen</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Base excess</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </other_outcome>
  <other_outcome>
    <measure>APGAR score</measure>
    <time_frame>1 min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </other_outcome>
  <other_outcome>
    <measure>APGAR score</measure>
    <time_frame>5 min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine infusion simultaneous with subarachnoid block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norepinephrine infusion simultaneous with subarachnoid block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Vasopressors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block</description>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <other_name>Vasopressors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:&#xD;
&#xD;
          -  18-45 years&#xD;
&#xD;
          -  Primipara or multipara&#xD;
&#xD;
          -  Singleton pregnancy ≥32 weeks&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status classification II to III&#xD;
&#xD;
          -  Scheduled for cesarean section under spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline blood pressure ≥180 mmHg&#xD;
&#xD;
          -  Body height &lt; 150 cm&#xD;
&#xD;
          -  Body weight &gt; 100 kg or body mass index (BMI) ≥ 40 kg/m2&#xD;
&#xD;
          -  Eclampsia or chronic hypertension&#xD;
&#xD;
          -  Hemoglobin &lt; 7g/dl&#xD;
&#xD;
          -  Fetal distress, or known fetal developmental anomaly&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinli Ni, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinli Ni, Dr.</last_name>
    <phone>86-951-674-3252</phone>
    <email>xinlini6@nyfy.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Chen, M.D.</last_name>
    <phone>86-951-674-3252</phone>
    <email>czzyxgp@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinli Ni, PhD, MD</last_name>
      <phone>+086 951-6743252</phone>
      <email>xinlii6@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine</keyword>
  <keyword>Postspinal anesthesia hypotension</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

